Brazil-based biotech companies on Tuesday said strict regulation in the country could keep biotech sugar cane off the market for as long as seven years.
Alellyx Applied Genomics plans to unveil its sugar cane variety for commercial use in 2013 or 2014 "if there are no major regulation setbacks," the company's scientific director said.

Full Story:

Related Summaries